The Latin America, Middle East and Africa Oncology Drugs Market would witness market growth of 11.1% CAGR during the forecast period (2023-2030).
The biosimilar oncology drugs are experiencing rapid growth. Biosimilars are highly similar versions of authorized biologic drugs and offer a more cost-effective alternative to branded therapies. This trend contributes to increased accessibility of cancer treatments, especially in regions where healthcare affordability is a significant concern. Integrating digital health technologies, including telemedicine, wearable devices, and real-time data analytics, is transforming cancer care. These technologies facilitate remote patient monitoring, personalized treatment adjustments, and the collection of real-world evidence, providing valuable insights for drug development and improving patient outcomes.
Lung cancer remains a significant health challenge, and the market is witnessing a surge in the development of novel therapeutics for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Targeted therapies such as EGFR and immune checkpoint inhibitors have shown promise in improving survival rates for lung cancer patients. Hematology-oncology is witnessing remarkable progress, particularly in treating hematological malignancies like lymphoma, leukemia, and multiple myeloma. Immunotherapies, including CAR-T cell therapies, have demonstrated unprecedented success in certain blood cancers, offering new hope for patients with limited treatment options.
The LAMEA region comprises countries with diverse populations and healthcare systems. Variations in healthcare infrastructure, access to medical services, and regulatory environments can signficantly impact the market differently in each country. Some countries in the LAMEA region have been increasing investments in healthcare infrastructure, including cancer treatment facilities and research centers. The need for targeted therapies, which can offer more precise and less toxic treatment options, may increase with the aging population. These aspects will boost the market growth in the coming years.
The Brazil region dominated the LAMEA Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,878.3 million by 2030. The Argentina region is showcasing a CAGR of 12.2% during (2023 - 2030). Additionally, The UAE region would register a CAGR of 10.8% during (2023 - 2030).
Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.
The biosimilar oncology drugs are experiencing rapid growth. Biosimilars are highly similar versions of authorized biologic drugs and offer a more cost-effective alternative to branded therapies. This trend contributes to increased accessibility of cancer treatments, especially in regions where healthcare affordability is a significant concern. Integrating digital health technologies, including telemedicine, wearable devices, and real-time data analytics, is transforming cancer care. These technologies facilitate remote patient monitoring, personalized treatment adjustments, and the collection of real-world evidence, providing valuable insights for drug development and improving patient outcomes.
Lung cancer remains a significant health challenge, and the market is witnessing a surge in the development of novel therapeutics for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Targeted therapies such as EGFR and immune checkpoint inhibitors have shown promise in improving survival rates for lung cancer patients. Hematology-oncology is witnessing remarkable progress, particularly in treating hematological malignancies like lymphoma, leukemia, and multiple myeloma. Immunotherapies, including CAR-T cell therapies, have demonstrated unprecedented success in certain blood cancers, offering new hope for patients with limited treatment options.
The LAMEA region comprises countries with diverse populations and healthcare systems. Variations in healthcare infrastructure, access to medical services, and regulatory environments can signficantly impact the market differently in each country. Some countries in the LAMEA region have been increasing investments in healthcare infrastructure, including cancer treatment facilities and research centers. The need for targeted therapies, which can offer more precise and less toxic treatment options, may increase with the aging population. These aspects will boost the market growth in the coming years.
The Brazil region dominated the LAMEA Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,878.3 million by 2030. The Argentina region is showcasing a CAGR of 12.2% during (2023 - 2030). Additionally, The UAE region would register a CAGR of 10.8% during (2023 - 2030).
Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.
Scope of the Study
Market Segments Covered in the Report:
By Indication- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancer
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Chemotherapy
- Hormonal Therapy
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Oncology Drugs Market by Indication
Chapter 6. LAMEA Oncology Drugs Market by Drug Class Type
Chapter 7. LAMEA Oncology Drugs Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Amgen, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
Methodology
LOADING...
